Extra treatment after surgery for lung cancer with high recurrence risk
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding an extra interventional treatment after surgery helps for lung cancer that has a high chance of returning, as shown by a positive minimal residual disease (MRD) test. The goal is to see if this approach can reduce the risk of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage II or III non-small cell lung cancer that can be removed with surgery.
- You have not had immunotherapy (such as PD-1 or PD-L1 inhibitors) before.
- Your tumor is negative for EGFR and ALK mutations.
- You are in generally good health, able to care for yourself, and your blood test results are within safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether adding a cancer-fighting immunotherapy (tislelizumab) and chemotherapy after surgery can lower the chance of lung cancer coming back. It uses “MRD” (measurable remaining disease) to help decide who may benefit the most after resection.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests whether giving a type of immunotherapy (sintilimab) along with chemotherapy before and after surgery to remove the main lung tumor can help people with advanced non-small cell lung cancer. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial is testing whether giving radiation therapy after surgery can help prevent lung cancer from coming back in people who have already had chemotherapy and immunotherapy before surgery. It is for patients whose cancer had spread to chest lymph nodes and who still have some cancer left in those nodes after surgery.
This trial looks at adding two immunotherapy drugs to radiation and chemotherapy for people with stage 3 lung cancer that cannot be removed by surgery. It compares giving immunotherapy during radiation versus giving it after radiation, to see which way may help control the cancer better.
Hear when a new DFS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.